Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Adalimumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Recipient : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
AbbVie, Eisai Receives Approval for Additional Indication of Humira to Treat Pyoderma Gangrenosum
Details : Approval is based on the data from a Japanese phase III clinical trial. The proportion of patients achieving at 100 of the target pyoderma gangrenosum ulcer area reduction at Week 26 of Humira administration was 54.5% in the trail.
Product Name : Humira
Product Type : Antibody
Upfront Cash : Inapplicable
November 27, 2020
Lead Product(s) : Adalimumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Recipient : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EDIT-101
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Recipient : Editas Medicine
Deal Size : Undisclosed
Deal Type : Termination
Editas Medicine Regains Full Global Rights to Ocular Medicines
Details : Editas has regained full global rights from Allergan to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber congenital amaurosis 10. The Original deal was announced in 2017.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $90.0 million
June 08, 2020
Lead Product(s) : EDIT-101
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Recipient : Editas Medicine
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Adalimumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 17, 2017
Lead Product(s) : Adalimumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adalimumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 18, 2010
Lead Product(s) : Adalimumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Eisai
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
